Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 2/2005

01-02-2005 | Leading Article

Drugs, QT Interval Prolongation and ICH E14

The Need to Get it Right

Author: Dr Rashmi R. Shah

Published in: Drug Safety | Issue 2/2005

Login to get access

Abstract

Regulatory concerns on the ability of an ever-increasing number of non-cardiovascular drugs to prolong the corrected QT (QTc) interval and induce potentially fatal ventricular tachyarrhythmias have culminated in initiatives to harmonise internationally the regulatory guidance on strategies by which to evaluate new drugs for this liability. The International Conference on Harmonisation (ICH) has released consensus texts for clinical (ICH topic E14) and non-clinical (ICH topic S7B) strategies as regulatory drafts for wider consultation.
Draft ICH E14 calls for a clinical ‘thorough QT/QTc study’ (typically in healthy volunteers) for new drugs with systemic bioavailability, regardless of the non-clinical data. This indifference to non-clinical data has sparked off a major debate, even among the regulators. The ‘thorough QT/QTc study’ is intended to determine whether a drug has a threshold pharmacological effect on cardiac repolarisation, as detected by QT/QTc prolongation, and proposes the use of a positive control to validate the study. The guideline recommends exploration of the effect of concentrations that are higher than those achieved following the anticipated therapeutic doses and, consequently, a negative ‘thorough QT/QTc study’, even in the presence of non-clinical data of concern, will almost always allow standard collection of on-therapy ECGs. The proposed threshold of a 5ms increase in mean placebo-corrected QTc interval for designating a study as positive for an effect, with all its implications for subsequent development of the drug and its regulatory assessment and labelling, has also generated a controversy.
This paper provides an overview commentary on some contentious or ambiguous aspects of draft ICH E14 with a view to stimulating a debate and inviting scientifically supported comments from stakeholders in order to ensure that the application of the ICH E14 strategy, when finalised and adopted, does not result in either restriction in the use (or even rejection) of a potentially beneficial drug or approval of an otherwise hazardous drug without the restrictions required to promote its safe use.
Literature
1.
Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54: 188–202PubMedCrossRef
2.
Priori SG. Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol 1998; 9: 1114–6PubMedCrossRef
3.
Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products (CPMP/986/96) [online]. EMEA; 1997 Dec 17; London, UK. Available from URL:http://​www.​emea.​eu.​int/​pdfs/​human/​swp/​09896-en.​pdf [Accessed 2004 Oct 16]
4.
US Food and Drug Administration/Health Canada. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: preliminary concept paper. 2002 Nov 15 [online]. Available from URL:http://​www.​fda.​gov/​ohrms/​dockets/​ac/​03/​briefing/​pubs%5Cprelim.pdf [Accessed 2004 Oct 16]
5.
Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci U S A 1994; 91: 3438–42PubMedCrossRef
6.
Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795–803PubMedCrossRef
7.
Morganroth J. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. Am J Cardiol 1993; 72: 10B–13PubMedCrossRef
8.
Dessertenne F. Ventricular tachycardia with 2 variable opposing foci [in French]. Arch Mal Coeur Vaiss 1966; 59: 263–72PubMed
9.
Stratmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J 1987; 113: 1470–82PubMedCrossRef
10.
Tzivoni D, Keren A, Banai S, et al. Terminology of torsades de pointes. Cardiovasc Drugs Ther 1991; 5: 505–7PubMedCrossRef
11.
Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med Clin North Am 2001; 85: 321–4112PubMedCrossRef
12.
13.
Yang T, Snyders D, Roden DM. Drug block of I(Kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001; 38: 737–44PubMedCrossRef
14.
Ben-David J, Zipes DP. α-Adrenoceptor stimulation and blockade modulates cesium-induced early afterdepolarizations and ventricular tachyarrhythmias in dogs. Circulation 1990; 82: 225–33PubMedCrossRef
15.
Lu HR, Remeysen P, De Clerck F. Nonselective IKr-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation. J Cardiovasc Pharmacol 2000; 36: 728–36PubMedCrossRef
16.
Noda T, Takaki H, Kurita T, et al. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J 2002; 23: 975–83PubMedCrossRef
17.
Fujikawa H, Sato Y, Arakawa H, et al. Induction of torsades de pointes by dobutamine infusion in a patient with idiopathic long QT syndrome. Intern Med 1998; 37: 149–52PubMedCrossRef
18.
Vos MA, van Opstal JM, Leunissen JD, et al. Electrophysiologic parameters and predisposing factors in the generation of drug-induced torsade de pointes arrhythmias. Pharmacol Ther 2001; 92: 109–22PubMedCrossRef
19.
Urao N, Shiraishi H, Ishibashi K, et al. Idiopathic long QT syndrome with early afterdepolarizations induced by epinephrine. Circ J 2004; 68: 587–91PubMedCrossRef
20.
Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15: 475–95PubMedCrossRef
21.
Antzelevitch C. Arrhythmogenic mechanisms of QT-prolonging drugs: is QT prolongation really the problem? J Electrocardiol 2004; 37Suppl.: 15–24PubMedCrossRef
22.
Li Y, Xue Q, Ma J, et al. Effects of imidapril on heterogeneity of action potential and calcium current of ventricular myocytes in infarcted rabbits. Acta Pharmacol Sin 2004; 25: 1458–63PubMed
23.
Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904–10PubMedCrossRef
24.
Watanabe N, Kobayashi Y, Tanno K, et al. Transmural dispersion of repolarization and ventricular tachyarrhythmias. J Electrocardiol 2004; 37: 191–200PubMedCrossRef
25.
Obreztchikova MN, Sosunov EA, Plotnikov A, et al. Developmental changes in IKr and IKs contribute to age-related expression of dofetilide effects on repolarization and proarrhythmia. Cardiovasc Res 2003; 59: 339–50PubMedCrossRef
26.
Di Diego JM, Berlardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003; 108: 1027–33PubMedCrossRef
27.
Aiba T, Shimizu W, Inagaki M, et al. Excessive increase in QT interval and dispersion of repolarization predict recurrent ventricular tachyarrhythmia after amiodarone. Pacing Clin Electrophysiol 2004; 27: 901–9PubMedCrossRef
28.
Shah RR. Interpretation of Clinical ECG Data: understanding the risk from non-antiarrhythmic drugs. In: Morganroth J, Gussak I, editors. Cardiac safety of noncardiac drugs: practical guidelines for clinical research and drug development. Totowa (NJ): Humana Press Inc, 2004: 259–98
29.
Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32–45PubMedCrossRef
30.
Shryock JC, Song Y, Wu L, et al. A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies. J Electrocardiol 2004; 37Suppl.: 34–9PubMedCrossRef
31.
Joshi A, Dimino T, Vohra Y, et al. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J Electrocardiol 2004; 37Suppl.: 7–14PubMedCrossRef
32.
Ficker E, Kuryshev YA, Dennis AT, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004; 66: 33–44PubMedCrossRef
33.
Kuryshev YA, Ficker E, Wang L, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 2005; 312: 316–23PubMedCrossRef
34.
Bonate PL. Rank power of metrics used to assess QTc interval prolongation by clinical trial simulation. J Clin Pharmacol 2000; 40: 468–74PubMedCrossRef
35.
Shah RR. Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J Electrocardiol 2005; 38: 10–8PubMedCrossRef
36.
Morganroth J. A definitive or thorough phase I QT ECG trial as a requirement for drug safety assessment. J Electrocardiol 2004; 37: 25–9PubMedCrossRef
37.
Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2003; 2: 439–47PubMedCrossRef
38.
DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151–85PubMedCrossRef
39.
Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome. Cardiology 2000; 94: 99–102PubMedCrossRef
40.
Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: a familial cause of sudden death. Circulation 2003; 108: 965–70PubMedCrossRef
41.
Makarov OM, Chuprova ON, Kiseleva OI. QT interval shortening in families with history of sudden death at young age [in Russian]. Kardiologiia 2004; 44: 51–6PubMed
42.
Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109: 30–5PubMedCrossRef
43.
Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004; 109: 2394–7PubMedCrossRef
44.
Extramiana F, Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 2004; 110: 3661–6PubMedCrossRef
Metadata
Title
Drugs, QT Interval Prolongation and ICH E14
The Need to Get it Right
Author
Dr Rashmi R. Shah
Publication date
01-02-2005
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 2/2005
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200528020-00003

Other articles of this Issue 2/2005

Drug Safety 2/2005 Go to the issue

Leading Article

Immunotoxicology

Current Opinion

Thiomersal in Vaccines

Review Article

Benefit-Risk Assessment of Sirolimus in Renal Transplantation

Leading Article

Interstitial Lung Disease in Lung Cancer

Review Article

The Safety of Newer Antidepressants in Pregnancy and Breastfeeding